Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Novan Inc (NOVN)

Novan Inc (NOVN)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.0941 -0.0311 (-24.84%) 07/25/23 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.0941 unch (unch) -
Quote Overview for Tue, Jul 25th, 2023
Day Low
0.0820
Day High
0.1396
Open 0.1368
Previous Close 0.1252 0.1252
Volume 7,190,000 7,190,000
Avg Vol 2,815,160 2,815,160
Stochastic %K 2.15% 2.15%
Weighted Alpha -79.79 -79.79
5-Day Change -0.0743 (-44.12%) -0.0743 (-44.12%)
52-Week Range 0.0820 - 3.3300 0.0820 - 3.3300
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,636
  • Shares Outstanding, K 28,015
  • Annual Sales, $ 23,680 K
  • Annual Income, $ -31,310 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta -0.06
  • Price/Sales 0.15
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.50
  • Most Recent Earnings $-0.54 on 05/15/23
  • Next Earnings Date 08/10/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +79.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0820 +14.76%
on 07/25/23
Period Open: 0.4200
0.6252 -84.95%
on 07/12/23
-0.3259 (-77.60%)
since 06/23/23
3-Month
0.0820 +14.76%
on 07/25/23
Period Open: 1.2800
1.3786 -93.17%
on 05/31/23
-1.1859 (-92.65%)
since 04/25/23
52-Week
0.0820 +14.76%
on 07/25/23
Period Open: 2.7900
3.3300 -97.17%
on 08/12/22
-2.6959 (-96.63%)
since 07/25/22

Most Recent Stories

More News
Novan: Q1 Earnings Snapshot

Novan: Q1 Earnings Snapshot

NOVN : 0.0941 (-24.84%)
Ligand Reports First Quarter 2023 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management...

LGND : 111.39 (-1.22%)
TVTX : 23.20 (-2.32%)
VKTX : 29.32 (-2.14%)
NOVN : 0.0941 (-24.84%)
NVS : 107.00 (-0.70%)
ANEB : 1.4400 (-2.04%)
Novartis: Q1 Earnings Snapshot

Novartis: Q1 Earnings Snapshot

NOVN : 0.0941 (-24.84%)
NVS : 107.00 (-0.70%)
Novartis: Q4 Earnings Snapshot

Novartis: Q4 Earnings Snapshot

NOVN : 0.0941 (-24.84%)
NVS : 107.00 (-0.70%)
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Novan, Inc. (Nasdaq: NOVN) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking...

LGND : 111.39 (-1.22%)
NOVN : 0.0941 (-24.84%)
ViaSat, Nvidia rise; Cal-Maine Foods falls

Stocks that traded heavily or had substantial price changes Thursday: ViaSat, Nvidia rise; Cal-Maine Foods falls

NOVN : 0.0941 (-24.84%)
NVS : 107.00 (-0.70%)
XOM : 107.35 (-3.01%)
GS : 649.00 (+0.27%)
CALM : 106.15 (-6.87%)
DVN : 33.97 (-3.27%)
VSAT : 8.98 (+1.70%)
Novan: Q3 Earnings Snapshot

Novan: Q3 Earnings Snapshot

NOVN : 0.0941 (-24.84%)
Novartis: Q3 Earnings Snapshot

Novartis: Q3 Earnings Snapshot

NOVN : 0.0941 (-24.84%)
NVS : 107.00 (-0.70%)
Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update

– Total revenue of $6.2 million for the second quarter 2022 – – Activities on track for submission of berdazimer gel, 10.3% (SB206) New Drug...

NOVN : 0.0941 (-24.84%)
Novan to Report Second Quarter 2022 Financial Results on August 11, 2022

DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second...

NOVN : 0.0941 (-24.84%)
Novan Satisfies $16.5 Million Outstanding Promissory Note

– Novan and Evening Post Group enter into a loan payoff and termination agreement, fully satisfying the promissory note and all related obligations – –...

NOVN : 0.0941 (-24.84%)
Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (SB206) in Patients with Molluscum Contagiosum in JAMA Dermatology

– The B-SIMPLE4 pivotal Phase 3 clinical study of berdazimer gel, 10.3% (SB206) is the largest interventional trial of molluscum contagiosum ("molluscum")...

NOVN : 0.0941 (-24.84%)
Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market

DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the Company’s...

NOVN : 0.0941 (-24.84%)
Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market

DURHAM, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a definitive...

NOVN : 0.0941 (-24.84%)
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology

– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of...

NOVN : 0.0941 (-24.84%)
Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update

– Transformational quarter for Novan, marked by acquisition of EPI Health – – Strongest quarter in total prescriptions for Rhofade increasing 47% from Q1...

NOVN : 0.0941 (-24.84%)
Novan to Report First Quarter 2022 Financial Results on May 16, 2022

DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first...

NOVN : 0.0941 (-24.84%)
Novan to Participate in the Virtual Investor Innovation in Dermatology Spotlight Event

Live moderated video webcast with members of the Novan management team on Tuesday, April 26th at 2:00 PM ET...

NOVN : 0.0941 (-24.84%)
Novan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology’s (AAD) 2022 Annual Meeting

DURHAM, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from its pivotal Phase...

NOVN : 0.0941 (-24.84%)
Novan, Inc. to Present at Two Upcoming Investor Conferences

DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford,...

NOVN : 0.0941 (-24.84%)
EPI Health Announces Acquisition by Novan, Inc. to Create Fully Integrated Specialty Dermatology Company

- Resulting entity to have broad portfolio of commercial product in dermatology and established pipeline of early and late-stage product candidates in development across multiple indications - Company...

NOVN : 0.0941 (-24.84%)
Novan Acquires EPI Health, a Specialty Dermatology Company

Acquisition Represents Forward Integration as a Commercial Organization...

NOVN : 0.0941 (-24.84%)
Novan Reports Full Year 2021 Financial Results and Provides Corporate Update

– First New Drug Application (NDA) submission targeted in Q4 2022 for lead program SB206 (berdazimer gel 10.3%) for molluscum contagiosum – – Ongoing...

NOVN : 0.0941 (-24.84%)
Novan to Report Full Year 2021 Financial Results on February 22, 2022

DURHAM, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year...

NOVN : 0.0941 (-24.84%)
Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference

DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s...

NOVN : 0.0941 (-24.84%)
Novan to Participate in the Virtual Investor Roundtable Event

– Live moderated video webcast discussion among management and Pediatric Dermatology Thought Leader on Wednesday, November 17th at 1:00 PM ET – DURHAM,...

NOVN : 0.0941 (-24.84%)
Novan: Q3 Earnings Snapshot

DURHAM, N.C. (AP) _ Novan Inc. (NOVN) on Wednesday reported a loss of $6.5 million in its third quarter.

NOVN : 0.0941 (-24.84%)
Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results

– Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead...

NOVN : 0.0941 (-24.84%)
Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19

– Data indicate that intranasal administration of SB019 formulation containing berdazimer sodium is well-tolerated and safe under the conditions of...

NOVN : 0.0941 (-24.84%)
JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies...

OTLK : 1.7400 (+4.19%)
AREC : 0.6276 (-1.51%)
CZO.VN : 0.225 (-11.76%)
CYTH : 0.9300 (+0.85%)
CNSP : 0.1038 (-5.64%)
SING : 0.0065 (-7.14%)
NVNO : 3.32 (+9.57%)
NOVN : 0.0941 (-24.84%)
VLON : 12.0000 (-13.04%)
CRPOF : 0.1700 (-13.04%)
MBRX : 0.4200 (-17.24%)

Business Summary

Novan, Inc. is a pharmaceutical company. It engaged in the development and commercialization of therapies using its nitric oxide platform for dermatology. The Company's product candidates primarily include SB204, SB206, SB208 and SB414 which are in pre-clinical trial stage. It develops product through...

See More

Key Turning Points

3rd Resistance Point 0.1861
2nd Resistance Point 0.1628
1st Resistance Point 0.1285
Last Price 0.0941
1st Support Level 0.0709
2nd Support Level 0.0476
3rd Support Level 0.0133

See More

52-Week High 3.3300
Fibonacci 61.8% 2.0893
Fibonacci 50% 1.7060
Fibonacci 38.2% 1.3227
Last Price 0.0941
52-Week Low 0.0820

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Increase Profitable Opportunities with Barchart's Technical Opinion